Arachidonic acid metabolites and α2-adrenoceptor-mediated glucagon secretion in rats

Kazunori Koyama, Hiroshi Hirose, Hiroshi Maruyama, Katsuhiko Itoh, Koichi Kido, Takao Saruta

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Effects of phospholipase A2 inhibitor, cyclooxygenase inhibitor and lipoxygenase inhibitor on glucagon secretion induced by the α2-adrenergic agonist clonidine were studied in the isolated perfused rat pancreas. The phospholipase A2 inhibitor mepacrine at 25 and 50 μmol/l significantly inhibited glucagon secretion induced by 0.1 μmol/l clonidine (P < 0.01, respectively), whereas 5 μmol/l mepacrine did not affect clonidine-induced glucagon secretion. Also, both 100 μmol/l acetylsalicilic acid (cyclooxygenase inhibitor) and 100 μmol/l caffeic acid (lipoxygenase inhibitor) significantly inhibited clonidine-induced glucagon secretion (P < 0.01, respectively), whereas neither 10 μmol/l acetylsalicylic acid nor 10 μmol/l caffeic acid affected clonidine-induced glucagon secretion. None of the drugs at the tested concentrations affected insulin secretion at a glucose concentration of 5.5 mmol/l. These results suggest that not only cyclooxygenase metabolites but also lipoxygenase metabolites are involved in the stimulation of glucagon secretion mediated through the α2-adrenergic receptors in perfused rat pancreas.

Original languageEnglish
Pages (from-to)229-232
Number of pages4
JournalDiabetes Research and Clinical Practice
Issue number3
Publication statusPublished - 1992 Jun


  • Alpha adrenergic receptors
  • Arachidonic acid
  • Glucagon
  • Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Arachidonic acid metabolites and α2-adrenoceptor-mediated glucagon secretion in rats'. Together they form a unique fingerprint.

Cite this